These results highlight the importance of including metabolically active bacteria to accurately model the CF lung to test the efficacy of CFTR-targeting therapies in the context of CF lung infection, and to understand the effects of these therapies on bacterial burden in pwCF. This evidence concerns the gene CFTR and cystic fibrosis.